Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells

Abstract

Accumulating evidence indicates that a sub-population of cancer cells with stem-like properties, termed tumor-initiating cells (T-ICs), exist in many different kinds of malignancies, which have a pivotal role in tumorigenesis, tumor progression, metastasis and post-treatment relapse. However, how the stem-like properties of T-ICs are regulated remains obscure. Our previous study showed that reduction of let-7 microRNA (miRNA) in breast tumor-initiating cells (BT-ICs) contributes to the maintenance of their self-renewal capacity and undifferentiated status. In this study we show the effect of mir-30 reduction on the stem-like features of BT-ICs. Similar to let-7, mir-30 is reduced in BT-ICs, and the protein level of Ubc9 (ubiquitin-conjugating enzyme 9) and ITGB3 (integrin β3), the target genes of mir-30, is markedly upregulated. Enforced constitutive expression of mir-30 in BT-ICs inhibits their self-renewal capacity by reducing Ubc9, and induces apoptosis through silencing ITGB3. On the contrary, blocking the miRNA with a specific antisense oligonucleotide (ASO) in differentiated breast cancer cells revived their self-renewal capacity. Furthermore, ectopic expression of mir-30 in BT-IC xenografts reduces tumorigenesis and lung metastasis in nonobese diabetic/severe combined immunodeficient mice, whereas blocking mir-30 expression enhances tumorigenesis and metastasis. Together, our data suggest mir-30 as one of the important miRNAs in regulating the stem-like features of T-ICs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Al-Hajj M . (2007). Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19: 61–64.

    PubMed  Google Scholar 

  • Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF . (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983–3988.

    Article  CAS  Google Scholar 

  • Chen CZ . (2005). MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768–1771.

    Article  CAS  Google Scholar 

  • Cho RW, Clarke MF . (2008). Recent advances in cancer stem cells. Curr Opin Genet Dev 18: 48–53.

    Article  CAS  Google Scholar 

  • Croce CM, Calin GA . (2005). miRNAs, cancer, and stem cell division. Cell 122: 6–7.

    Article  CAS  Google Scholar 

  • Dalerba P, Cho RW, Clarke MF . (2007). Cancer stem cells: models and concepts. Annu Rev Med 58: 267–284.

    Article  CAS  Google Scholar 

  • Dalerba P, Clarke MF . (2007). Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 1: 241–242.

    Article  CAS  Google Scholar 

  • Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. (2003). in vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17: 1253–1270.

    Article  CAS  Google Scholar 

  • Gilmore AP . (2005). Anoikis. Cell Death Differ 12 (Suppl 2): 1473–1477.

    Article  CAS  Google Scholar 

  • Glinsky GV, Berezovska O, Glinskii AB . (2005). Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503–1521.

    Article  CAS  Google Scholar 

  • Gupta PB, Chaffer CL, Weinberg RA . (2009). Cancer stem cells: mirage or reality? Nat Med 15: 1010–1012.

    Article  CAS  Google Scholar 

  • Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L et al. (2009). MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 4: e6816.

    Article  Google Scholar 

  • Jordan CT, Guzman ML, Noble M . (2006). Cancer stem cells. N Engl J Med 355: 1253–1261.

    Article  CAS  Google Scholar 

  • Mizejewski GJ . (1999). Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222: 124–138.

    Article  CAS  Google Scholar 

  • Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT . (2005). A role for Ubc9 in tumorigenesis. Oncogene 24: 2677–2683.

    Article  CAS  Google Scholar 

  • Muller S, Hoege C, Pyrowolakis G, Jentsch S . (2001). SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2: 202–210.

    Article  CAS  Google Scholar 

  • Park SW, Hu X, Gupta P, Lin YP, Ha SG, Wei LN . (2007). SUMOylation of Tr2 orphan receptor involves Pml and fine-tunes Oct4 expression in stem cells. Nat Struct Mol Biol 14: 68–75.

    Article  CAS  Google Scholar 

  • Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al. (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506–5511.

    Article  CAS  Google Scholar 

  • Pontier SM, Muller WJ . (2009). Integrins in mammary-stem-cell biology and breast-cancer progression—a role in cancer stem cells? J Cell Sci 122: 207–214.

    Article  CAS  Google Scholar 

  • Watanabe M, Takahashi K, Tomizawa K, Mizusawa H, Takahashi H . (2008). Developmental regulation of Ubc9 in the rat nervous system. Acta Biochim Pol 55: 681–686.

    CAS  PubMed  Google Scholar 

  • Wu F, Zhu S, Ding Y, Beck WT, Mo YY . (2009). MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 15: 1550–1557.

    Article  CAS  Google Scholar 

  • Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. (2007). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.

    Article  CAS  Google Scholar 

  • Zhan M, Zhao H, Han ZC . (2004). Signalling mechanisms of anoikis. Histol Histopathol 19: 973–983.

    CAS  Google Scholar 

  • Zhang Z, Liao B, Xu M, Jin Y . (2007). Post-translational modification of POU domain transcription factor Oct-4 by SUMO-1. FASEB J 21: 3042–3051.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Natural Science Foundation of China Grant (30921140312, 30830110, 30772550, 30973396, 30525022, 30671930, 30973505), 973 (2010CB912800, 2009CB521706, 2005CB724605) Projects from the Ministry of Science and Technology of China, and Natural Science Foundation of Guangdong Province (8251008901000011).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E Song.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, F., Deng, H., Yao, H. et al. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29, 4194–4204 (2010). https://doi.org/10.1038/onc.2010.167

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.167

Keywords

This article is cited by

Search

Quick links